BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 29
• 30

• 

  Manufacturing

  2025: The Year Trump Pushed Manufacturing Into the Spotlight

  A push to reshore some drug production and progress in advanced manufacturing technologies have been prominent trends this year, industry leaders say.

  December 23, 2025

   · 

  4 min read

   · 

  Nick Paul Taylor
• 

  Business

  ICYMI: 5 BioSpace Features From 2025 That Stand the Test of Time

  Of all the stories we published this year, these deep dives by BioSpace editors stand out as relevant re-reads going into the New Year.

  December 23, 2025

   · 

  6 min read

   · 

  Jef Akst
• 

  Legal

  Investment Banker Accused of Leaking Pharma M&A Secrets in $41M Insider Trading Scheme

  The banker allegedly shared details of a series of multibillion-dollar buyouts by companies including AbbVie, GSK and Pfizer.

  December 23, 2025

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  Clinical research

  Pfizer Reports Patient Death in Long-Term Trial of Hympavzi for Hemophilia A

  The patient, who died on December 14, was originally enrolled in a Phase III study in 2022 and transitioned into an extension phase in 2023.

  December 23, 2025

   · 

  1 min read

   · 

  Annalee Armstrong
• 

  GLP-1

  Novo’s Wegovy Pill Wins Obesity Approval, Securing Lead in Oral GLP-1 Race

  Analysts called the approval a much-needed win for Novo Nordisk, but warned that the company could struggle to grow sales once rival drugs come to market.

  December 23, 2025

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  Neuroscience

  Neurocrine’s Valbenazine Fails Phase III Neurodevelopmental Disorder Trial

  Analysts said the outcome is disappointing because there are no approved treatments for dyskinetic cerebral palsy, but the setback had little impact on Neurocrine’s valuation.

  December 23, 2025

   · 

  2 min read

   · 

  Nick Paul Taylor
• Press Releases

  ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer

  December 23, 2025

   · 

  19 min read
• Press Releases

  DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer

  December 23, 2025

   · 

  20 min read
• Press Releases

  Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer

  December 23, 2025

   · 

  7 min read
• Press Releases

  Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH® CTC enumeration to guide treatment decisions in a specific metastatic breast cancer subtype

  December 23, 2025

   · 

  4 min read